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Background
Approximately 10 percent of women with invasive
epithelial ovarian cancer (EOC) carry deleterious germ-
line mutations in BRCA1 or BRCA2. However, the
impact of these mutations on ovarian cancer prognosis
remains unclear.
Methods
We performed an international multi-center study of
1,470 EOC cases with pathogenic germline mutations in
BRCA1 (1,134) or BRCA2 (336) and 2,814 non-carriers.
Our goal was to further characterize the survival of
BRCA carriers with EOC compared to non-carriers and
to determine whether BRCA1 and BRCA2 carriers show
similar survival patterns. Cox proportional hazards
regression, both unadjusted and adjusted for other prog-
nostic variables, was used to measure differences in
overall survival during the five years following diagnosis.
Results
The five-year overall survival was 36 percent for non-
carriers, 44 percent for BRCA1 carriers and 52 percent
for BRCA2 carriers. After adjusting for study and year of
diagnosis, BRCA1 and BRCA2 carriers showed a more
favorable survival than non-carriers (BRCA1, HR=0.78;
95% CI=0.68-0.89, P=2x10-4; BRCA2, HR = 0.61; 95%
CI=0.50-0.76, P=6x10-6;). These survival differences
remained after adjustment for stage, grade, histology
and age at diagnosis (BRCA1, HR=0.73, 95% CI=0.64-
0.84, P=2x10-5; BRCA2, HR = 0.49, 95% CI=0.39-0.61,
P=3x10-10).
Conclusions
We observed a significantly improved survival in germ-
line BRCA1 and BRCA2 mutation carriers with EOC
compared to non-carriers. BRCA2 carriers had the most
favorable outcome with a distinct clinical course from
BRCA1 carriers. The magnitude of the differences we
observed highlight the need for clinical trials in EOC to
be stratified by BRCA1/2 status and suggest that the
routine testing of women presenting with high-grade
serous EOC may be warranted.
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